Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, notes yesterday’s article in the Mail on Sunday about the Company and a collaboration with the University of Oxford.

A further announcement regarding this collaboration will be made in due course.

Enquiries:

Hemogenyx Pharmaceuticals Limited	www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder Via Walbrook PR Dr Robin Campbell, Chairman	Via Walbrook PR
Optiva Securities Ltd	Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP	Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited	Tel: +44 (0)20 7469 0930
Lucy Williams, Duncan Vasey
Walbrook PR/strong>	Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Paul McManus	Mob: +44 (0)7980 541 893

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, HemoGenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. HemoGenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company’s leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. HemoGenyx’s two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.